Ilyang to enter Phase I/II studies for new investigational leukemia drug

Ilyang Pharm says it will conduct Phase I and II trials simultaneously for its new leukemia medicine “IY5511” in 10 hospitals at home and abroad for 18 months, after getting the IND approval from the Korea Food and Drug Administration.

“Based on the positive results of preclinical studies, IY5511 may have the potential to bring additional benefits to patients who suffer from leukemia,” a Ily...